Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.

about

A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma.

P2860

Q47143379-81182075-2006-4404-88E5-68E4F3729407

P2860

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.

Item

http://www.wikidata.org/entity/Q42257155

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.

@en

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.

@nl

type

Item

label

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.

@en

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.

@nl

prefLabel

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.

@en

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.

@nl

P1476

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.

@en

P2093

Melissa Bersanelli

http://www.w3.org/2001/XMLSchema#string

P2860

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures.

Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma.

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

P304

627-636

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758834017724314

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sebastiano Buti

Melissa Bersanelli

P577

2017-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28974985

http://www.w3.org/2001/XMLSchema#string

P932

5613858

http://www.w3.org/2001/XMLSchema#string

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.

about

P2860

P2860

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932